Efficacy of melatonin in the treatment of patients with COVID‐19: A systematic review and meta‐analysis of randomized controlled trials

Abstract

This study investigated the effect of melatonin on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). We searched PubMed, the Web of Science, the Cochrane Library, Ovid MEDLINE, and Clinicaltrials.gov for randomized controlled trials (RCTs) published before September 11, 2021. Only RCTs that compared the clinical efficacy of melatonin with a placebo in the treatment of patients with COVID-19 were included. The primary outcome measure was the clinical recovery rate. We included three RCTs in this meta-analysis. Melatonin 3 mg three times daily was administered in one RCT, and 3 or 6 mg daily before bedtime in the other two trials. Treatment duration was 14 days in two RCTs and 7 days in one trial. The clinical recovery rates were 94.2% (81/86) and 82.4% (70/85

N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19

“…Apart from preventing the depletion of inorganic sulfate when these drugs are given, sulfur-donor supplements would complement the anti-inflammatory drugs through their synergistic immune-modulatory action [3]. Even though quercetin and melatonin have been shown to be very beneficial in the early treatment of COVID-19 [190][191][192], they also require sulfation to be metabolised. NAC should therefore also be considered as an adjunct to these early treatment protocols.…”

Melatonin use for SARS‐CoV‐2 infection: Time to diversify the treatment portfolio

“…We were pleased to read the publication by Lan et al 1 which included a meta‐analysis of the randomized controlled trials (RCTs) in which melatonin was used as a treatment for COVID‐19. Sixty‐two studies were considered, but only three RCTs (published before September 11, 2021) met the requirements for inclusion.…”

“…Sanchez‐Gonzalez et al 7 found that melatonin treatment of seriously‐ill COVID patients led to a reduced mortality rate. Since the cutoff date (September 2021) for the meta‐analysis described above, 1 an additional study was published using melatonin to treat COVID patients. This clinical trial investigated the impact of melatonin on the mortality of severely‐diseased COVID patients and reported a significantly reduced death rate.…”

Melatonin increased hypoxia‐inducible factor (HIF) by inhibiting prolyl hydroxylase: A hypothesis for treating anaemia, ischaemia, and covid‐19

“… 10 Also, a meta‐analysis of three randomised controlled trials confirmed that MLT consumption increases clinical recovery rate, decreases risk of intensive care unit admission, and mortality rate in covid‐19 patients. 17 However, further large‐scale researches are needed to decisive conclusion.…”